Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Bibliographic Details
Main Authors:	Othus, Megan, Wood, Brent L., Stirewalt, Derek L., Estey, Elihu H., Petersdorf, Stephen H., Appelbaum, Frederick R., Erba, Harry P., Walter, Roland B.
Format:	Online
Language:	English
Published:	2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053842/

Similar Items

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
by: Zhou, Yi, et al.
Published: (2016)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
by: Othus, M, et al.
Published: (2016)

New drug approvals in acute myeloid leukemia: what's the best end point?
by: Estey, E, et al.
Published: (2016)

Immunophenotypic Characterisation And Evaluation Of Minimal Residual Disease (Mrd) In Acute Leukaemia Patients In Sarawak By Flow Cytometry
by: Mohamad Razif, Othman
Published: (2013)

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients
by: Coombes, RC, et al.
Published: (2005)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
by: Nagafuji, Koji, et al.
Published: (2013)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
by: Estey, Elihu
Published: (2013)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
by: Weber, Axel, et al.
Published: (2012)

Rare e14a3 (b3a3) BCR-ABL Fusion in Chronic Myeloid Leukemia in India: The Threats and Challenges in Monitoring Minimal Residual Disease (MRD)
by: Vaniawala, Salil, et al.
Published: (2013)

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
by: Salipante, Stephen J., et al.
Published: (2014)

Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
by: Burmeister, Thomas, et al.
Published: (2012)

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia
by: Walter, Roland B., et al.
Published: (2015)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
by: Shiomi, Daisuke, et al.
Published: (2013)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
by: Bar, Merav, et al.
Published: (2014)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
by: Walter, Roland B., et al.
Published: (2014)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
by: Alizad Ghandforoush, Nasrin, et al.
Published: (2016)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
by: Kayser, S, et al.
Published: (2016)

The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia
by: Pogosova-Agadjanyan, Era L., et al.
Published: (2013)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
by: Walter, Roland B., et al.
Published: (2014)

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
by: Feller, N, et al.
Published: (2013)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
by: Venn, N C, et al.
Published: (2012)

Relapsing acute myeloid leukemia presenting as hypopyon uveitis
by: Hegde, Sapna P, et al.
Published: (2011)

Comparison of microRNA expression in hippocampus and the marginal division (MrD) of the neostriatum in rats
by: Shu, Si Yun, et al.
Published: (2013)

Evolutionary Conservation of the Ribosomal Biogenesis Factor Rbm19/Mrd1: Implications for Function
by: Kallberg, Yvonne, et al.
Published: (2012)

Multiple RNA interactions position Mrd1 at the site of the small subunit pseudoknot within the 90S pre-ribosome
by: Segerstolpe, Åsa, et al.
Published: (2013)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
by: Lambert, Juliette, et al.
Published: (2014)

Low PKCa expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome
by: Milani, Gloria, et al.
Published: (2014)

Partial remission, residual symptoms, and relapse in depression
by: Paykel, E.S.
Published: (2008)

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling
by: Bai, Ju, et al.
Published: (2013)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
by: Del Principe, Maria Ilaria, et al.
Published: (2016)

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
by: Bibault, Jean-Emmanuel, et al.
Published: (2015)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
by: Grubovikj, Rada M., et al.
Published: (2012)

Postremission sequential monitoring of minimal residual disease by WT1 Q‐PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients
by: Malagola, Michele, et al.
Published: (2015)

MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors
by: Morris, Valerie A., et al.
Published: (2013)

Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing
by: Ding, Li, et al.
Published: (2012)

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
by: Logan, A C, et al.
Published: (2013)

Assessment of Minimal Residual Disease in Ewing Sarcoma
by: Wagner, Lars M., et al.
Published: (2012)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
by: Nishihori, Taiga, et al.
Published: (2016)

Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia
by: LUO, SHENG, et al.
Published: (2013)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
by: Ramos, Nestor R., et al.
Published: (2015)